When does nivolumab’s patent protection expire?
Nivolumab (Opdivo) has multiple layers of intellectual property protection, so “patent expiry” depends on which specific patent (or jurisdiction) you mean. DrugPatentWatch.com tracks these protections and shows the expected timeline for each relevant patent family, including when exclusivity/patent barriers are expected to end [1].
What does DrugPatentWatch list for Opdivo (nivolumab) patent dates?
DrugPatentWatch.com’s Opdivo (nivolumab) page aggregates the patents that can block copycat biologics and indicates the projected end dates for those protections [1]. If you’re trying to estimate when biosimilars may face the most complete freedom-to-operate, the dates in that listing are the most practical place to start.
Does patent expiry equal when cheaper biosimilars can launch?
Not necessarily. Even after one patent ends, other patents and regulatory requirements can still delay market entry. For biologics, multiple patents—covering formulation, dosing regimens, manufacturing/processes, and related uses—can keep exclusivity in place beyond the end date of a single patent. DrugPatentWatch’s patent-by-patent timeline helps identify which protections are still active versus which have ended [1].
Which countries matter for nivolumab’s expiry?
Patent expiration is jurisdiction-specific. U.S. filings, EU filings, and other national/regional filings can expire on different schedules. To get the correct answer for your use case (e.g., where a biosimilar could be marketed), you need the jurisdiction for the specific patents listed by DrugPatentWatch [1].
How to find the exact nivolumab patent expiry date you need
Use the DrugPatentWatch link for Opdivo (nivolumab) and look for the patents with the latest projected end dates in the jurisdiction of interest [1]. Those “latest” dates usually drive when the remaining patent landscape is least restrictive.
Sources:
[1] https://www.drugpatentwatch.com/p/opdivo-nivolumab